高危子宫内膜癌辅助治疗:患者与医生的偏好差异及共享决策启示
基于PORTEC-3试验数据的权衡问卷研究,纳入171例接受辅助盆腔放疗(联合或不联合化疗)的高危子宫内膜癌患者及63名妇科肿瘤多学科医生。患者愿意选择放化疗而非单纯放疗所需的最小生存获益中位数显著高于医生(10% vs 5%,p=0.02)。双方均将生存获益视为决策中最重要的因素,其次是长期症状。
要点
- 患者选择放化疗所需最小生存获益中位数高于医生(10% vs 5%)。
- 合并症与年龄较大降低患者对放化疗的偏好,放化疗史与计算能力提高偏好。
- 共享决策时应向患者充分说明生存获益与长期症状的权衡。
核心结论
- 高危子宫内膜癌患者与医生之间及各自内部对放化疗最小期望生存获益存在相当大差异,总体上患者需要更高获益才倾向选择放化疗。
研究设计与样本
- 基于PORTEC-3试验数据的权衡问卷研究,纳入171例接受辅助盆腔放疗(联合或不联合化疗)的高危子宫内膜癌患者和63名妇科肿瘤多学科医生。
主要发现
- 患者选择放化疗所需最小生存获益中位数显著高于医生(10% vs 5%,p=0.02)。
- 患者与医生均将生存获益评为决策中最重要因素,其次是长期症状。
- 年龄较大(OR 0.92 [95%CI 0.87-0.97];p=0.003)与合并症(OR 0.34 [95%CI 0.12-0.89];p=0.035)与较低放化疗偏好相关。
- 计算能力较好(OR 1.2 [95%CI 1.05-1.36],p=0.011)与有放化疗史(OR 25.0 [95%CI 8.8-91.7];p<0.001)与较高放化疗偏好相关。
临床怎么用
- 面向高危子宫内膜癌患者进行辅助治疗决策时,应结合其年龄、合并症、计算能力与既往治疗经历解释放化疗的生存获益与长期症状,支持共享决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Decision making regarding adjuvant therapy for high-risk endometrial cancer is complex. The aim of this study was to determine patients' and clinicians' minimally desired survival benefit to choose chemoradiotherapy over radiotherapy alone. Moreover, influencing factors and importance of positive and negative treatment effects (i.e. attribute) were investigated. METHODS: Patients with high-risk endometrial cancer treated with adjuvant pelvic radiotherapy with or without chemotherapy and multidisciplinary gynaecologic oncology clinicians completed a trade-off questionnaire based on PORTEC-3 trial data. RESULTS: In total, 171 patients and 63 clinicians completed the questionnaire. Median minimally desired benefit to make chemoradiotherapy worthwhile was significantly higher for patients versus clinicians (10% vs 5%, p = 0.02). Both patients and clinicians rated survival benefit most important during decision making, followed by long-term symptoms. Older patients (OR 0.92 [95%CI 0.87-0.97]; p = 0.003) with comorbidity (OR 0.34 [95% CI 0.12-0.89]; p = 0.035) had lower preference for chemoradiotherapy, while patients with better numeracy skills (OR 1.2 [95%CI 1.05-1.36], p = 0.011) and chemoradiotherapy history (OR 25.0 [95%CI 8.8-91.7]; p < 0.001) had higher preference for chemoradiotherapy. CONCLUSIONS: There is a considerable difference in minimally desired survival benefit of chemoradiotherapy in high-risk endometrial cancer among and between patients and clinicians. Overall, endometrial cancer patients needed higher benefits than clinicians before preferring chemoradiotherapy.
引用
- Post CCB, Mens JWM, Haverkort MAD, et al. Patients' and clinicians' preferences in adjuvant treatment for high-risk endometrial cancer: Implications for shared decision making. Gynecol Oncol. 2021. PMID: 33712276. doi:10.1016/j.ygyno.2021.03.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。